Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells.
about
Clinical perspectives of TRAIL: insights into central nervous system disordersHuman monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.TRAIL/TRAIL receptor system and susceptibility to multiple sclerosisEarly detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells.Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells.Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.B lymphocytes are resistant to death receptor 5-induced apoptosis.Genetic modification of pigs as organ donors for xenotransplantation.TRAIL modulates the immune system and protects against the development of diabetes.Cellular FLICE-inhibitory protein: an attractive therapeutic target?The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL.Stimulation of macrophages with the β-glucan produced by aureobasidium pullulans promotes the secretion of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)Apoptosis in autoimmune diabetes: the fate of beta-cells in the cleft between life and death.HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells.TRAIL and its receptors as targets for cancer therapy.Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatinDeath ligands and autoimmune demyelination.Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb.Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.Following TRAIL's path in the immune system.Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironmentMolecular signatures of T-cell inhibition in HIV-1 infection.Distinct roles of TNF-related apoptosis-inducing ligand (TRAIL) in viral and bacterial infections: from pathogenesis to pathogen clearance.Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D.The effect of TRAIL molecule on cell viability in in vitro beta cell culture.Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells.TRAIL limits excessive host immune responses in bacterial meningitis.Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy.Mycobacterium tuberculosis infection causes different levels of apoptosis and necrosis in human macrophages and alveolar epithelial cells.Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression.Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.Serum soluble tumor necrosis factor-related apoptosis-inducing ligand level after allogeneic hematopoietic cell transplantation.Molecular cloning, expression analysis and assignment of the porcine tumor necrosis factor superfamily member 10 gene (TNFSF10) to SSC13q34-->q36 by fluorescence in situ hybridization and radiation hybrid mapping.Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells.TRAIL gene expression analysis in multiple sclerosis patients.An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis.
P2860
Q26766570-01FE3E02-FCEB-47B3-B452-386F0658F652Q33523440-AB0728A2-039E-42C5-BD4E-21A0E8A8449FQ33981373-F047CDC3-ED11-4F80-8627-5A7089DA1202Q34368959-97A8E343-8522-46BB-B248-710E671FE71EQ34537114-4ED7EB62-C0C4-472D-8E90-DA0E223FA9ABQ34699537-53E148EC-40A4-45BB-BFBF-CB8426BABB44Q34712125-9A9F35AD-A06D-40C2-8FA5-2DB643B90292Q34728945-F632552A-57BB-41F0-9F74-BF783E41B07DQ35016869-4E67834F-1418-4606-AC95-BD6725B5476EQ35155962-3D0557DC-F1E4-46A6-A877-80A0F7CA95E9Q35186676-6F64D8F8-E9FD-499D-81AD-58EEBCB3031BQ35403047-1C6CA695-C4B3-4B7B-94E5-A94DE32CFED8Q35602205-F2E239DD-38E6-4F62-9032-BD5D91E857E8Q35612740-4B8AB7B0-59E9-4DAC-A6B5-EC43D52CA5F4Q35673465-1E117D87-C8CA-466B-A4CB-0B003D33A036Q35927476-4E9914F2-815F-4CF6-BE78-050CACFC8E09Q36370581-D131D453-4F32-413A-B634-E22FCCBD55F7Q36535669-C5475BF3-A0FB-4574-B220-A591C20525EDQ36927030-B42BA8FF-EA82-4F46-B038-AECD2850DBA0Q37071856-FBB62260-2703-443F-A834-1BEC072D262AQ37486214-97B69789-0D58-4E81-853B-9EC68F7A4FCAQ37498946-9B2FB00F-128C-41C4-AED9-C390E15D63FDQ37520325-17C85302-6C0E-46CA-BC22-F535E3896F95Q38091548-5A7BDC82-8F63-4FDC-BCE8-5C04F15CB75AQ38760809-6496CE58-A83C-4637-9FAF-68EDAD141EF0Q38984981-7B2B43F6-DEED-4AC9-B922-7A216B0930D6Q39798367-32EC4AC1-6246-4B02-A628-59F971EF8DDEQ40127613-A81F5057-BAB8-4969-87BD-11AE2DEAF601Q40715403-CC6F4D6F-3019-4C60-859F-6F77D5F7F215Q41837909-334C6975-E145-4CA5-9C87-051CC9C064D7Q42471247-9C587A98-5FF1-449A-B0DA-3D9A61F84184Q44553442-D9EB445E-7BC5-435D-BB9D-6B1FD95C15EFQ45226653-B0E73169-2688-456C-BD86-01760DEC4252Q46829895-164A7F21-A49A-4D65-B864-C7E17CFD0738Q47771919-82F29621-73A3-4BAC-8AB9-0EA7576817EEQ48125951-BD4B4803-92D8-41D7-A11E-C726F9F7568EQ50909745-0EC6B7F8-5D16-443C-ABAD-32FBB86B4E72Q51045188-FDEB9F9A-F34E-42AF-9587-83CB780384DFQ51606946-755C8FD0-7E81-43D9-BA09-3FA18FC57E2FQ52777580-FB21865C-EF2F-448C-ABEF-4A0243A44E92
P2860
Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Death ligand TRAIL induces no ...... auto)antigen-specific T cells.
@en
type
label
Death ligand TRAIL induces no ...... auto)antigen-specific T cells.
@en
prefLabel
Death ligand TRAIL induces no ...... auto)antigen-specific T cells.
@en
P2093
P50
P1476
Death ligand TRAIL induces no ...... auto)antigen-specific T cells.
@en
P2093
Bibiane Seeger
Jan D Lünemann
Uwe Wendling
P304
P356
10.4049/JIMMUNOL.168.10.4881
P407
P577
2002-05-01T00:00:00Z